Abstract: The outlook today for patients with CML is much brighter than just a few years ago. In this article, we review our current understanding of this disease, diagnostic and treatment approaches. A comprehensive literature search strategy was performed by an electronic search of the databases (CINAHL, MEDLINE, and the Cochrane Library (The Cochrane Register of Clinical Trials) for relevant studies that were published up to December, 2017 for studies discussing, chronic myeloid leukemiain English language. Consensus exists that imatinib treatment is the standard approach to the therapy of CML, and this modality will be determined in the future against all new therapies. The current addition of the highly potent TKIs nilotinib and dasatinib has further improved the armamentarium versus CML however also posed new challenges. Initially, the function of these new compounds in modern algorithms of CML treatment is still unidentified and must be defined. In spite of having revealed impressive reaction rates in patients after imatinib failure or intolerance, the duration of these reactions will be identified with longer follow-up. Their role in frontline treatment for CML will likewise have to be defined. Second, as our resources for managing CML improve, the refinement in molecular monitoring must improve in parallel. In this regard, the lack of consistency amongst various laboratories in BCR-ABL transcript results by present PCR technologies is still a continuous issue.
Keywords: Chronic Myeloid Leukemia (CML), BCR-ABL.
Title: Clinical Diagnosis and Therapy Approach toward Chronic Myeloid Leukemia
Author: Amal Almass Alblushi, Amnah Ahmed Alhuwayji
International Journal of Healthcare Sciences
ISSN 2348-5728 (Online)
Research Publish Journals
